Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats

Detalhes bibliográficos
Autor(a) principal: Peres, Fernanda Fiel [UNIFESP]
Data de Publicação: 2016
Outros Autores: Leyin, Raquel [UNIFESP], Suiama, Mayra Akimi [UNIFESP], Diana, Mariana Cepollaro [UNIFESP], Gouvea, Douglas Albuquerque [UNIFESP], Almeida, Valeria [UNIFESP], Santos, Camila Mauricio [UNIFESP], Lungato, Lisandro [UNIFESP], Zuardi, Antonio W., Hallak, Jaime E. C., Crippa, Jose A., D'Almeida, Vania [UNIFESP], Silva, Regina Helena da [UNIFESP], Abilio, Vanessa Costhek [UNIFESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.3389/fphar.2016.00343
https://repositorio.unifesp.br/handle/11600/57099
Resumo: Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. In Parkinson's disease patients, CBD is able to attenuate the psychotic symptoms induced by L-DOPA and to improve quality of life. Repeated administration of reserpine in rodents induces motor impairments that are accompanied by cognitive deficits, and has been applied to model both tardive dyskinesia and Parkinson's disease. The present study investigated whether CBD administration would attenuate reserpine-induced motor and cognitive impairments in rats. Male Wistar rats received four injections of CBD (0.5 or 5 mg/kg) or vehicle (days 2-5). On days 3 and 5, animals received also one injection of 1 mg/kg reserpine or vehicle. Locomotor activity, vacuous chewing movements, and catalepsy were assessed from day 1 to day 7. On days 8 and 9, we evaluated animals' performance on the plus-maze discriminative avoidance task, for learning/memory assessment. CBD (0.5 and 5 mg/kg) attenuated the increase in catalepsy behavior and in oral movements - but not the decrease in locomotion induced by reserpine. CBD (0.5 mg/kg) also ameliorated the reserpine-induced memory deficit in the discriminative avoidance task. Our data show that CBD is able to attenuate motor and cognitive impairments induced by reserpine, suggesting the use of this compound in the pharmacotherapy of Parkinson's disease and tardive dyskinesia.
id UFSP_3b67ec128b9527f3487b66fc8ce8c817
oai_identifier_str oai:repositorio.unifesp.br/:11600/57099
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in RatsreserpinecannabidiolParkinson's diseasetardive dyskinesiaschizophreniaratCannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. In Parkinson's disease patients, CBD is able to attenuate the psychotic symptoms induced by L-DOPA and to improve quality of life. Repeated administration of reserpine in rodents induces motor impairments that are accompanied by cognitive deficits, and has been applied to model both tardive dyskinesia and Parkinson's disease. The present study investigated whether CBD administration would attenuate reserpine-induced motor and cognitive impairments in rats. Male Wistar rats received four injections of CBD (0.5 or 5 mg/kg) or vehicle (days 2-5). On days 3 and 5, animals received also one injection of 1 mg/kg reserpine or vehicle. Locomotor activity, vacuous chewing movements, and catalepsy were assessed from day 1 to day 7. On days 8 and 9, we evaluated animals' performance on the plus-maze discriminative avoidance task, for learning/memory assessment. CBD (0.5 and 5 mg/kg) attenuated the increase in catalepsy behavior and in oral movements - but not the decrease in locomotion induced by reserpine. CBD (0.5 mg/kg) also ameliorated the reserpine-induced memory deficit in the discriminative avoidance task. Our data show that CBD is able to attenuate motor and cognitive impairments induced by reserpine, suggesting the use of this compound in the pharmacotherapy of Parkinson's disease and tardive dyskinesia.Univ Fed Sao Paulo, Dept Psychiat, Interdisciplinary Lab Clin Neurosci, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Pharmacol, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Psychobiol, Sao Paulo, BrazilUniv Sao Paulo, Dept Neurosci & Behav, Ribeirao Preto, BrazilNatl Council Sci & Technol Dev, Natl Inst Translat Med, Ribeirao Preto, BrazilInterdisciplinary Laboratory of Clinical Neurosciences, Department of Psychiatry, Universidade Federal de São Paulo (UNIFESP), São Paulo, BrazilDepartment of Pharmacology, Universidade Federal de São Paulo (UNIFESP), São Paulo, BrazilDepartment of Psychobiology, Universidade Federal de São Paulo (UNIFESP), São Paulo, BrazilWeb of ScienceFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)FAPESP: 2010/07994-3FAPESP: 2015/03354-3CNPq/MS/SCTIE/DECIT: 26/2014CNPq/MS/SCTIE/DECIT: 466805/2014-4Frontiers Media Sa2020-07-31T12:47:48Z2020-07-31T12:47:48Z2016info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion-application/pdfhttp://dx.doi.org/10.3389/fphar.2016.00343Frontiers In Pharmacology. Lausanne, v. 7, p. -, 2016.10.3389/fphar.2016.00343WOS000384265900001.pdf1663-9812https://repositorio.unifesp.br/handle/11600/57099WOS:000384265900001engFrontiers In PharmacologyLausanneinfo:eu-repo/semantics/openAccessPeres, Fernanda Fiel [UNIFESP]Leyin, Raquel [UNIFESP]Suiama, Mayra Akimi [UNIFESP]Diana, Mariana Cepollaro [UNIFESP]Gouvea, Douglas Albuquerque [UNIFESP]Almeida, Valeria [UNIFESP]Santos, Camila Mauricio [UNIFESP]Lungato, Lisandro [UNIFESP]Zuardi, Antonio W.Hallak, Jaime E. C.Crippa, Jose A.D'Almeida, Vania [UNIFESP]Silva, Regina Helena da [UNIFESP]Abilio, Vanessa Costhek [UNIFESP]reponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-11T19:41:05Zoai:repositorio.unifesp.br/:11600/57099Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-11T19:41:05Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats
title Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats
spellingShingle Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats
Peres, Fernanda Fiel [UNIFESP]
reserpine
cannabidiol
Parkinson's disease
tardive dyskinesia
schizophrenia
rat
title_short Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats
title_full Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats
title_fullStr Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats
title_full_unstemmed Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats
title_sort Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats
author Peres, Fernanda Fiel [UNIFESP]
author_facet Peres, Fernanda Fiel [UNIFESP]
Leyin, Raquel [UNIFESP]
Suiama, Mayra Akimi [UNIFESP]
Diana, Mariana Cepollaro [UNIFESP]
Gouvea, Douglas Albuquerque [UNIFESP]
Almeida, Valeria [UNIFESP]
Santos, Camila Mauricio [UNIFESP]
Lungato, Lisandro [UNIFESP]
Zuardi, Antonio W.
Hallak, Jaime E. C.
Crippa, Jose A.
D'Almeida, Vania [UNIFESP]
Silva, Regina Helena da [UNIFESP]
Abilio, Vanessa Costhek [UNIFESP]
author_role author
author2 Leyin, Raquel [UNIFESP]
Suiama, Mayra Akimi [UNIFESP]
Diana, Mariana Cepollaro [UNIFESP]
Gouvea, Douglas Albuquerque [UNIFESP]
Almeida, Valeria [UNIFESP]
Santos, Camila Mauricio [UNIFESP]
Lungato, Lisandro [UNIFESP]
Zuardi, Antonio W.
Hallak, Jaime E. C.
Crippa, Jose A.
D'Almeida, Vania [UNIFESP]
Silva, Regina Helena da [UNIFESP]
Abilio, Vanessa Costhek [UNIFESP]
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Peres, Fernanda Fiel [UNIFESP]
Leyin, Raquel [UNIFESP]
Suiama, Mayra Akimi [UNIFESP]
Diana, Mariana Cepollaro [UNIFESP]
Gouvea, Douglas Albuquerque [UNIFESP]
Almeida, Valeria [UNIFESP]
Santos, Camila Mauricio [UNIFESP]
Lungato, Lisandro [UNIFESP]
Zuardi, Antonio W.
Hallak, Jaime E. C.
Crippa, Jose A.
D'Almeida, Vania [UNIFESP]
Silva, Regina Helena da [UNIFESP]
Abilio, Vanessa Costhek [UNIFESP]
dc.subject.por.fl_str_mv reserpine
cannabidiol
Parkinson's disease
tardive dyskinesia
schizophrenia
rat
topic reserpine
cannabidiol
Parkinson's disease
tardive dyskinesia
schizophrenia
rat
description Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. In Parkinson's disease patients, CBD is able to attenuate the psychotic symptoms induced by L-DOPA and to improve quality of life. Repeated administration of reserpine in rodents induces motor impairments that are accompanied by cognitive deficits, and has been applied to model both tardive dyskinesia and Parkinson's disease. The present study investigated whether CBD administration would attenuate reserpine-induced motor and cognitive impairments in rats. Male Wistar rats received four injections of CBD (0.5 or 5 mg/kg) or vehicle (days 2-5). On days 3 and 5, animals received also one injection of 1 mg/kg reserpine or vehicle. Locomotor activity, vacuous chewing movements, and catalepsy were assessed from day 1 to day 7. On days 8 and 9, we evaluated animals' performance on the plus-maze discriminative avoidance task, for learning/memory assessment. CBD (0.5 and 5 mg/kg) attenuated the increase in catalepsy behavior and in oral movements - but not the decrease in locomotion induced by reserpine. CBD (0.5 mg/kg) also ameliorated the reserpine-induced memory deficit in the discriminative avoidance task. Our data show that CBD is able to attenuate motor and cognitive impairments induced by reserpine, suggesting the use of this compound in the pharmacotherapy of Parkinson's disease and tardive dyskinesia.
publishDate 2016
dc.date.none.fl_str_mv 2016
2020-07-31T12:47:48Z
2020-07-31T12:47:48Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.3389/fphar.2016.00343
Frontiers In Pharmacology. Lausanne, v. 7, p. -, 2016.
10.3389/fphar.2016.00343
WOS000384265900001.pdf
1663-9812
https://repositorio.unifesp.br/handle/11600/57099
WOS:000384265900001
url http://dx.doi.org/10.3389/fphar.2016.00343
https://repositorio.unifesp.br/handle/11600/57099
identifier_str_mv Frontiers In Pharmacology. Lausanne, v. 7, p. -, 2016.
10.3389/fphar.2016.00343
WOS000384265900001.pdf
1663-9812
WOS:000384265900001
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Frontiers In Pharmacology
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv -
application/pdf
dc.coverage.none.fl_str_mv Lausanne
dc.publisher.none.fl_str_mv Frontiers Media Sa
publisher.none.fl_str_mv Frontiers Media Sa
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268433072652288